Yeo Vale Rotary Ride for Prostate Cancer Research
Sat 15th June 2019 at 09.00 - Sun 16th June 2019 - 09.00
Get on your bike for Prostate Cancer Research
On Father’s Day weekend 2019 (15/16 June) Rotary clubs around the country are holding bike rides to raise thousands of pounds for their chosen prostate cancer charities. These charities offer tremendous support for those affected by the cancer, whether patients, relatives or friends.
As part of this national event, Yeo Vale Rotary Club is inviting members of the public of all abilities to enjoy some light fitness fun and saddle up for a static indoor exercise bike ride (in 15-minute segments). To be held at Progress Performance on the Lynx Estate in Yeovil in aid of Cancer Research UK. Those with limited ability will be able to use either a recumbent exercise bike (with seat & backrest) or an upper body trainer using arms rather than legs. Apart from your sponsorship or donations there is no charge for taking part.
Please come along to help us raise funds towards Rotary Ride's target of £40,000 for this valuable work. If you would like to get pedalling for the Yeo Vale Rotary Ride please contact Imogen at Progress Performance on 01935 706326 or by email at firstname.lastname@example.org
Rob Harris, proprietor of Progress Performance comments: “I’m delighted to be able to support the Rotary Club of Yeo Vale in holding this Rotary Ride cycling event at Progress Performance in aid prostate cancer research by our chosen charity, Cancer Research UK”.
Becky Trout, Cancer Research UK’s Local Fundraising Manager, explains: “Prostate cancer does not care who it affects or the devastation it causes to patients and their families. We do care. That’s why we’re supporting this Rotary Rider event against prostate cancer. One man dying every 45 minutes is a startling figure and we are doing what we can to bring that down.”
* Prostate cancer is the most common cancer in men in the UK, but more than 8 in 10 (84%) of patients now survive their disease for 10 years or more. We are at the heart of this progress - playing pivotal roles in the development of treatments like abiraterone and intensity modulated radiotherapy.
* Cancer Research UK's research has played a role in developing 8 of the world's top 10 cancer drugs.
At CRUK, we provide funding for the full research pipeline, from the basic laboratory research through to clinical trials. Thanks to this carefully crafted pipeline, our researchers have played a part in developing 8 of the world's top 10 cancer drugs.
Abiraterone is an important treatment for advanced prostate cancer. Abiraterone works by blocking the production of male hormones that can fuel the growth of prostate cancers.
Our work led to the availability of abiraterone on the NHS, and it is now regularly used to treat patients with advanced prostate cancer. Our researchers were first involved in the drug's development in the early 1990s. They identified and tested a compound in the lab, referred to as '3', and were able to show that it could block hormone production. The CRUK Strathclyde Formulation Unit packaged '3' into a pill renamed as abiraterone, which was then tested rigorously in people with cancer in clinical trials. We supported the initial, early phase I and II clinical studies before the final phase III trials, which were carried out with the help of the pharmaceutical industry. Finally, in 2012 we lobbied to make the drug available on the NHS.
* For the year 2017-2018 we spent £413 million on our research, and over £22 million on prostate cancer research.